- Home
- CFLT vs LEGN Comparison
CFLT vs LEGN Comparison
Compare CFLT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFLT
- LEGN
- Stock Information
- Founded
- CFLT 2014
- LEGN 2014
- Country
- CFLT United States
- LEGN United States
- Employees
- CFLT N/A
- LEGN N/A
- Industry
- CFLT EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CFLT Technology
- LEGN Health Care
- Exchange
- CFLT Nasdaq
- LEGN Nasdaq
- Market Cap
- CFLT 8.1B
- LEGN 7.0B
- IPO Year
- CFLT 2021
- LEGN 2020
- Fundamental
- Price
- CFLT $23.12
- LEGN $31.08
- Analyst Decision
- CFLT Buy
- LEGN Strong Buy
- Analyst Count
- CFLT 30
- LEGN 13
- Target Price
- CFLT $31.00
- LEGN $79.42
- AVG Volume (30 Days)
- CFLT 6.8M
- LEGN 1.6M
- Earning Date
- CFLT 04-30-2025
- LEGN 05-13-2025
- Dividend Yield
- CFLT N/A
- LEGN N/A
- EPS Growth
- CFLT N/A
- LEGN N/A
- EPS
- CFLT N/A
- LEGN N/A
- Revenue
- CFLT $1,017,525,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CFLT $21.73
- LEGN $65.96
- Revenue Next Year
- CFLT $18.93
- LEGN $52.55
- P/E Ratio
- CFLT N/A
- LEGN N/A
- Revenue Growth
- CFLT 24.11
- LEGN 112.46
- 52 Week Low
- CFLT $17.79
- LEGN $29.27
- 52 Week High
- CFLT $37.90
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CFLT 54.42
- LEGN 39.41
- Support Level
- CFLT $20.46
- LEGN $30.25
- Resistance Level
- CFLT $24.50
- LEGN $33.30
- Average True Range (ATR)
- CFLT 1.09
- LEGN 1.53
- MACD
- CFLT 0.29
- LEGN -0.18
- Stochastic Oscillator
- CFLT 74.44
- LEGN 26.21
About CFLT Confluent Inc.
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.